Atria Investments Inc Buys Shares of 7,354 Evolent Health, Inc. (NYSE:EVH)

Atria Investments Inc bought a new position in shares of Evolent Health, Inc. (NYSE:EVH) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 7,354 shares of the technology company’s stock, valued at approximately $208,000.

A number of other institutional investors have also made changes to their positions in EVH. Quarry LP purchased a new position in shares of Evolent Health during the 2nd quarter worth approximately $32,000. GAMMA Investing LLC boosted its position in shares of Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after buying an additional 1,556 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Evolent Health during the second quarter worth $61,000. Quest Partners LLC acquired a new stake in shares of Evolent Health in the second quarter valued at $87,000. Finally, Point72 DIFC Ltd purchased a new stake in shares of Evolent Health in the 2nd quarter valued at $148,000.

Evolent Health Trading Down 2.9 %

NYSE:EVH opened at $11.25 on Friday. Evolent Health, Inc. has a 1 year low of $11.17 and a 1 year high of $35.00. The stock has a market cap of $1.31 billion, a P/E ratio of -12.36 and a beta of 1.58. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a 50-day simple moving average of $23.26 and a 200-day simple moving average of $23.77.

Analysts Set New Price Targets

A number of brokerages recently commented on EVH. Citigroup lowered their target price on Evolent Health from $33.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Stephens lowered shares of Evolent Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $38.00 to $16.00 in a research note on Friday, November 8th. Barclays dropped their price objective on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, November 11th. JPMorgan Chase & Co. reduced their target price on shares of Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $20.00 price target on shares of Evolent Health in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $25.90.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.